Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma

BACKGROUND: Pancreatic ductal carcinoma (PDC) is a challenging diagnosis with a particularly poor prognosis, even after curative surgery (median survival: <30 months). The prognosis of borderline resectable pancreatic cancer (BR-PDC) is even worse. We describe a patient with BR-PDC who achieved s...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Sukhun, Sana, Khalidi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151079/
https://www.ncbi.nlm.nih.gov/pubmed/37138969
http://dx.doi.org/10.3332/ecancer.2023.1535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151079/
https://www.ncbi.nlm.nih.gov/pubmed/37138969
http://dx.doi.org/10.3332/ecancer.2023.1535

Ejemplares similares